Results 51 to 60 of about 11,328,563 (174)

Early binding of anti-amyloid antibodies to CAA drives complement activation, inflammation and ARIA in mice

Molecular Neurodegeneration
Anti-amyloid antibody treatment for Alzheimer’s disease is linked to Amyloid-Related Imaging Abnormalities (ARIA), including vasogenic edema (ARIA-E) and microhemorrhages (ARIA-H), especially in ApoE ε4/4 carriers.
Praveen Bathini, Stephan Schilling, Jens-Ulrich Rahfeld, David M. Holtzman, Takaomi C. Saido, Cynthia A. Lemere   +5 more
doaj   +1 more source

Navigating the Challenges of Shared Decision‐Making in Amyloid Immunotherapy for Alzheimer's Disease

European Journal of Neurology, Volume 33, Issue 11, November 2026.
ABSTRACT Background Anti‐amyloid therapies (AATs), such as lecanemab and donanemab, represent a major therapeutic development for early Alzheimer's disease (AD). However, safety risks and uncertainties regarding long‐term effects make treatment decisions complex.
Grâce François, Robin Michalon, Thomas Tannou, Philippe Damier, Sonia Desmoulin, Thibaud Lebouvier   +5 more
wiley   +1 more source

Anti-Amyloid Imaging Abnormality in the Era of Anti-Amyloid Beta Monoclonal Antibodies: Recent Updates for the Radiologist

Journal of the Korean Society of Radiology
Lecanemab and donanemab have received full U.S. Food and Drug Administration (FDA) approval, and subsequently, lecanemab has been approved by the Korean FDA and it has recently entered commercial use in Korea.
So Yeong Jeong, Chong Hyun Suh, Jae-Sung Lim, Yangsean Choi, Ho Sung Kim, Sang Joon Kim, Jae-Hong Lee   +6 more
doaj   +1 more source

Recognising Mild Cognitive Impairment and Early Alzheimer's Disease in General and Psychiatric Practice: Clinical Clues and Appropriate Referral

Psychogeriatrics, Volume 26, Issue 6, November 2026.
ABSTRACT Early cognitive decline may become evident through changes in daily activities or behaviour before it is apparent in a brief consultation. This selective narrative review supports case‐finding and appropriate referral in general and psychiatric practice.
Kengo Shimoda
wiley   +1 more source

Memory Consolidation and ARIA in Individuals Receiving Anti-amyloid Monoclonal Antibodies

The Journal of Prevention of Alzheimer's Disease
Amyloid related imaging abnormalities (ARIA) are the most significant risk associated with the use of anti-amyloid monoclonal antibodies (MAB) for Alzheimer’s disease (AD).
Marc W. Haut, Camila Vieira Ligo Teixeira, Patrick D. Worhunsky, Rashi I. Mehta, Joseph E. Malone, Melanie Ward, Cierra M. Keith, Holly E. Phelps, Stephanie Pockl, Nafiisah Rajabalee, Khalid Sharif, Gary Marano, Pierre-Francois D’Haese, Ali R. Rezai   +13 more
doaj   +1 more source

Longitudinal clinical outcomes after amyloid clearance in aducanumab phase 3 studies

Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.
Abstract INTRODUCTION Anti‐amyloid antibody clinical trials with a high proportion of participants reaching treatment‐related amyloid clearance (TRAC) had positive clinical outcomes. We evaluated the aducanumab phase 3 program to determine whether TRAC during the double‐blind period was likewise associated with clinical benefit.
Menglan Pang, Holly M. Brothers, John O'Gorman, Jennifer Murphy, Yuval Zabar, Tyler Lasky, Changyu Shen, Ivana Rubino, David Knopman   +8 more
wiley   +1 more source

Experience with donanemab over a 1‐year period: observations of side effects and compliance from a regional specialty medical center

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION The anti‐amyloid monoclonal antibody donanemab (Kisunla™) treats patients with mild cognitive impairment or mild Alzheimer's disease. METHODS This study highlights 51 patients who received at least one donanemab infusion at our memory center
Lisa B. E. Shields, Hannah S. Hust, Gregory E. Cooper, Theresa Kluthe, Rachel N. Hart, Andrew P. Thaliath, Brandon C. Dennis, Stephanie W. Freeman, Jessica F. Cain, Whoy Y. Shang, Kendall M. Wasz, Adam T. Orr, Christopher B. Shields, Shirish S. Barve, Kenneth G. Pugh   +14 more
doaj   +1 more source

Insights into the transcriptomic heterogeneity of brain endothelial cells in normal aging and Alzheimer’s disease

Neural Regeneration Research
Drug development for Alzheimer’s disease is extremely challenging, as demonstrated by the repeated failures of amyloid-β-targeted therapeutics and the controversies surrounding the amyloid-β cascade hypothesis.
Qian Yue, Shang Li, Chon Lok Lei, Huaibin Wan, Zaijun Zhang, Maggie Pui Man Hoi   +5 more
doaj   +1 more source

The value of timely treatment with anti‐amyloid therapy for Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.
Abstract INTRODUCTION Anti‐amyloid therapies can slow Alzheimer's disease (AD) progression; diagnostic and treatment delays might reduce their value. METHODS Using dynamic microsimulation, we estimated the gross societal value of anti‐amyloid treatment for Americans with early symptomatic AD. A treatment scenario slowed the rate of clinical progression
Jack M. Chapel, Bryan Tysinger, Hossein Pourmand, Dana Goldman, Paul Aisen, for the Alzheimer's Disease Neuroimaging Initiative   +5 more
wiley   +1 more source

Alzheimer's Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for ARIA Monitoring [PDF]

With the full FDA approval and centers for Medicare & Medicaid services (CMS) coverage of lecanemab and donanemab, a growing number of practices are offering anti-amyloid immunotherapy to appropriate patients with cognitive impairment (MCI) or mild ...
Barakos, Jerome A, Benayoun, Marc Daniel, Poussaint, Tina Young, Raji, Cyrus A, Ramanan, Vijay K, Tanabe, Jody, Chiang, Gloria C, Jack, Clifford R, Pillai, Jay J, Yu, Fang F, ASNR Alzheimer’s, ARIA, and Dementia Study Group, Zaharchuk, Greg, Zeinah, Michael, Whitlow, Christopher T, Tanenbaum, Lawrence, Franceschi, Ana M, Andrews, Trevor J, Bash, Suzie, Benzinger, Tammie S, Barkhof, Frederik, Cogswell, Petrice M   +20 more
core   +1 more source